Diabetic Peripheral Neuropathy Pipeline Insights, Clinical Trials Assessment, Emerging Drugs and Companies 2025 | DelveInsight

DelveInsight's, "Diabetic Peripheral Neuropathy Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Diabetic Peripheral Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our comprehensive Diabetic Peripheral Neuropathy Pipeline Report to stay informed about the latest advancements. Download copy now @ Diabetic Peripheral Neuropathy Pipeline Outlook- https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Diabetic Peripheral Neuropathy Pipeline Report
• In January 2025:- Helixmith Co. Ltd.- The purpose of this 6-month extension study (VMDN-003-2b) is to evaluate the durability of efficacy and long-term safety of intramuscular administration of Engensis or Placebo that was administered in the double-blind, randomized, VMDN-003-2 Placebo-controlled Phase 3 Study. No treatments will be administered in this VMDN-003-2b extension study. The combined overall duration of the VMDN-003-2 and VMDN-003-2b studies will be 12 months.
• DelveInsight's Diabetic Peripheral Neuropathy pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Diabetic Peripheral Neuropathy treatment.
• The leading Diabetic Peripheral Neuropathy Companies such as Apurano Pharmaceuticals, Novaremed, Trevena, Helixmith, Applied Therapeutics, WinSanTor, Centrexion Therapeutics, Praetego and others.
• Promising Diabetic Peripheral Neuropathy Therapies such as VM202, WST-057, LX9211, and others.

Dive into our Diabetic Peripheral Neuropathy Pipeline Report to uncover promising therapies and breakthroughs. Gain insights that could shape the future of oncology @ Diabetic Peripheral Neuropathy Treatment Therapies- https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Diabetic Peripheral Neuropathy Emerging Drugs Profile

• Adezunap: Apurano Pharmaceuticals
Adezunap (also known as AP707) is a investigational drug developed by Apurano Pharmaceuticals. It utilizes the company's PuranoTec® bio-nanotechnology to enhance the absorption and bioavailability, the active ingredient. This innovative approach overcomes the challenges of water-insoluble by using lipid-based nanoparticles for effective oromucosal delivery. Adezunap is being developed primarily for chronic pain management, a field with significant unmet therapeutic needs. The drug recently underwent a Phase I clinical trial (SELECT I), where it demonstrated favorable pharmacokinetics, tolerability, and safety. Healthy male participants were given a single dose of Adezunap, and despite relatively high blood levels and its active metabolite, no psychotropic effects or serious adverse events were observed. Compared to existing drugs, Adezunap showed a higher systemic exposure, which may translate to enhanced efficacy without compromising safety. This makes it a promising candidate for conditions such as neuropathic pain and chronic pain syndromes. The drug is currently being investigated in the Phase III stage of development for the treatment of Diabetic Peripheral Neuropathy.

• NRD.E1: Novaremed
NRD.E1 (or NRD135S.E1) is a new chemical entity, that is orally available and being developed to replace opioids for the treatment of painful diabetic peripheral neuropathy (PDPN). The mechanism of action of NRD.E1 is different to that of approved pain therapies as the investigational drug does not bind to or interact with receptors for opioids, serotonin, GABA, NMDA, it does also not interact with sodium or calcium channels or kinases and a large number of additional pain-related targets. NRD.E1 decreases phosphorylation of Y-507 of Lyn kinase, which has been shown to be involved in upregulation of P2X4, the purinergic receptor, critical for pain processing in the central nervous system. NRD.E1 has shown efficacy in multiple preclinical models for neuropathic pain. In addition, NRD.E1 has demonstrated a very good tolerability profile in the 13-week toxicology studies both in rats and dogs. Currently, the drug is in the Phase II stage of its development for the treatment of Diabetic Peripheral Neuropathy

• TRV045: Trevena
TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. Through a collaboration with the National Institutes of Health, Trevena is also exploring TRV045 as a potential treatment for epilepsy. S1P receptors are located throughout the body, including the central nervous system, where they are believed to play a role in modulating neurotransmission and membrane excitability. Trevena's discovery efforts have identified a family of compounds that are highly selective for the S1P1 receptor. TRV045 reversed thermal hyperalgesia, a measure of neuropathic pain, in nonclinical models of diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy. TRV045 was not associated with lymphopenia and produced no changes in blood pressure, heart rate, or respiratory function at or above pharmacologically active doses in nonclinical studies. TRV045 is an investigational product and is not yet approved by the FDA. The drug is currently in Phase I stage of its development for the treatment of Diabetic Peripheral Neuropathy.

Download the Diabetic Peripheral Neuropathy Pipeline Report to discover partnership opportunities and collaborate in driving impactful solutions forward @ Diabetic Peripheral Neuropathy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Diabetic Peripheral Neuropathy Companies
Apurano Pharmaceuticals, Novaremed, Trevena, Helixmith, Applied Therapeutics, WinSanTor, Centrexion Therapeutics, Praetego and others.

Diabetic Peripheral Neuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Diabetic Peripheral Neuropathy Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Dive into our detailed Diabetic Peripheral Neuropathy Pipeline Report to discover groundbreaking advancements shaping the future of cancer treatment @ Diabetic Peripheral Neuropathy Products, Companies, and Unmet Needs- https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Diabetic Peripheral Neuropathy Pipeline Report
• Coverage- Global
• Diabetic Peripheral Neuropathy Companies- Helixmith Co., Ltd., WinSanTor, Inc., Lexicon Pharmaceuticals, Inc, Vertex Pharmaceuticals Incorporated, Biogen, Mitsubishi Tanabe Pharma Corporation, Eli Lilly and Company, Apurano Pharmaceuticals GmbH, and others.
• Diabetic Peripheral Neuropathy Therapies- VM202, WST-057, LX9211, and others.
• Diabetic Peripheral Neuropathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Diabetic Peripheral Neuropathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Gain valuable insights into emerging therapies and innovations with our Diabetic Peripheral Neuropathy Pipeline Report @ Diabetic Peripheral Neuropathy Market Drivers and Barriers, Future Perspectives and Analyst Views- https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Diabetic Peripheral Neuropathy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Diabetic Peripheral Neuropathy- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. VM202: Helixmith Co., Ltd.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. LX9211: Lexicon Pharmaceuticals, Inc
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Diabetic Peripheral Neuropathy Key Companies
21. Diabetic Peripheral Neuropathy Key Products
22. Diabetic Peripheral Neuropathy- Unmet Needs
23. Diabetic Peripheral Neuropathy- Market Drivers and Barriers
24. Diabetic Peripheral Neuropathy- Future Perspectives and Conclusion
25. Diabetic Peripheral Neuropathy Analyst Views
26. Diabetic Peripheral Neuropathy Key Companies
27. Appendix

List of Top Selling Market Research Reports in 2025

Varicose Vein Treatment Devices Market - https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Vascular Access Devices Market - https://www.delveinsight.com/report-store/vascular-access-device-market
Indwelling Catheters Market - https://www.delveinsight.com/report-store/indwelling-catheters-market
Healthare Competitive Benchmarking - https://www.delveinsight.com/consulting/competitive-benchmarking-services
Lymphoedema Market - https://www.delveinsight.com/report-store/lymphoedema-market
Pacemakers Market - https://www.delveinsight.com/report-store/pacemakers-market
Myeloproliferative Neoplasms Market - https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market
Surgical Mask & Respirator Market - https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Nk Cell Therapy Market - https://www.delveinsight.com/report-store/nk-cell-therapy-market
Novel Drug Delivery Devices Market - https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Testicular Neoplasm Market - https://www.delveinsight.com/report-store/testicular-cancer-pipeline-insight
Phototherapies For Psoriasis Market - https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
Skin Neoplasm Market - https://www.delveinsight.com/report-store/nonmelanoma-skin-cancer-market
Microscopy Device Market - https://www.delveinsight.com/report-store/microscopy-device-market
Bone Growth Stimulator Market - https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Urea Cycle Disorders Market - https://www.delveinsight.com/report-store/urea-cycle-disorders-market
Antibody Drug Conjugate Market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
Total Knee Arthroplasty Market - https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Cardiac Implantable Electronic Devices Market - https://www.delveinsight.com/report-store/cardiac-implantable-electronic-devices-cieds-market
Dyspepsia Market - https://www.delveinsight.com/report-store/functional-dyspepsia-epidemiology-forecast-insight
Lactose Intolerance Market - https://www.delveinsight.com/report-store/lactose-intolerance-market
Medical Marijuana Market - https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Asperger Syndrome Market - https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
Catheter Stabilization Devices Market - https://www.delveinsight.com/report-store/catheter-stabilization-securement-device-market

About Us

DelveInsight is a leading healthare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healtcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.